Interpace Diagnostics Group Statistics
Interpace Diagnostics Group (PF4) Stock Statistics & Valuation Metrics
Total Valuation
Interpace Diagnostics Group has a market cap or net worth of EUR 36.81M. The enterprise value is EUR 43.46M.
- Market Cap
- EUR 36.81M
- Enterprise Value
- EUR 43.46M
Share Statistics
Interpace Diagnostics Group has 5,901,962 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 5,901,962
- Owned by Insiders
- 90.61%
- Owned by Institutions
- ―
Financial Efficiency
Interpace Diagnostics Group’s return on equity (ROE) is 1.10 and return on invested capital (ROIC) is 14.00%.
- Return on Equity (ROE)
- 1.10
- Return on Assets (ROA)
- 0.73
- Return on Invested Capital (ROIC)
- 14.00%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 379.69K
- Profits Per Employee
- 240.93K
- Employee Count
- 102
- Asset Turnover
- 1.14
- Inventory Turnover
- 13.10
Valuation Ratios
The current PE Ratio of Interpace Diagnostics Group is 0.23. Interpace Diagnostics Group’s PEG ratio is 0.00.
- PE Ratio
- 0.23
- PS Ratio
- 1.01
- PB Ratio
- 1.48
- Price to FCF
- 8.92
- Price to Operating Cash Flow
- 7.71
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Interpace Diagnostics Group had revenue of 38.73M and earned 24.57M in profits. Earnings per share was 27.75.
- Revenue
- 38.73M
- Gross Profit
- 24.13M
- Operating Income
- 4.08M
- Pretax Income
- 3.77M
- Net Income
- 24.57M
- EBITDA
- 4.76M
- Earnings Per Share (EPS)
- 27.75
Cash Flow
In the last 12 months, operating cash flow was 4.46M and capital expenditures -353,000, giving a free cash flow of 4.10M billion.
- Operating Cash Flow
- 4.46M
- Free Cash Flow
- 4.10M
- Free Cash Flow per Share
- 0.74
Dividends & Yields
Interpace Diagnostics Group pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 11.22%
- Earnings Yield
- 71.17%
Stock Price Statistics
- Beta
- -0.24
- 52-Week Price Change
- 34.72%
- 50-Day Moving Average
- 6.40
- 200-Day Moving Average
- 7.01
- Relative Strength Index (RSI)
- 26.69
- Average Volume (3m)
- 600
Important Dates
Interpace Diagnostics Group upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Interpace Diagnostics Group as a current ratio of 1.94, with Debt / Equity ratio of 5.29%
- Current Ratio
- 1.94
- Quick Ratio
- 1.72
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.28
- Interest Coverage Ratio
- 24.31
Taxes
In the past 12 months, Interpace Diagnostics Group has paid -21.21M in taxes.
- Income Tax
- -21.21M
- Effective Tax Rate
- -5.62
Enterprise Valuation
Interpace Diagnostics Group EV to EBITDA ratio is 7.22, with an EV/FCF ratio of 8.50.
- EV to Sales
- 0.96
- EV to EBITDA
- 7.22
- EV to Free Cash Flow
- 8.50
- EV to Operating Cash Flow
- 7.83
Balance Sheet
Interpace Diagnostics Group has EUR 2.69M in cash and marketable securities with EUR 974.00K in debt, giving a net cash position of EUR 1.71M billion.
- Cash & Marketable Securities
- EUR 2.69M
- Total Debt
- EUR 974.00K
- Net Cash
- EUR 1.71M
- Net Cash Per Share
- EUR 0.29
- Tangible Book Value Per Share
- EUR 4.20
Margins
Gross margin is 63.75%, with operating margin of 11.53%, and net profit margin of 67.64%.
- Gross Margin
- 63.75%
- Operating Margin
- 11.53%
- Pretax Margin
- 10.77%
- Net Profit Margin
- 67.64%
- EBITDA Margin
- 13.37%
- EBIT Margin
- 11.15%
Analyst Forecast
The average price target for Interpace Diagnostics Group is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -26.06%
- EPS Growth Forecast
- 480.57%
